Evaluation of the GATIS score for predicting prognosis in rectal neuroendocrine neoplasms

Abstract

The GATIS score, developed by Zeng et al, represents a significant advancement in predicting the prognosis of patients with rectal neuroendocrine neoplasms (R-NENs). This study, which included 1408 patients from 17 major medical centres in China over 12 years, introduces a novel prognostic model based on the tumour grade, T stage, tumour size, age, and the prognostic nutritional index. Compared with traditional methods such as the World Health Organization classification and TNM staging systems, the GATIS score has superior predictive power for overall survival and progression-free survival. With a C-index of 0.915 in the training set and 0.812 in the external validation set, the GATIS score’s robustness and reliability are evident. The study’s use of a large, multi-centre cohort and rigorous validation processes underscore its significance. The GATIS score offers clinicians a powerful tool to accurately predict patient outcomes, guide treatment decisions, and improve follow-up strategies. This development represents a crucial step forwards in the management of R-NENs, addressing the complexity and variability of these tumours and setting a new benchmark for future research and clinical practice.

Keywords: GATIS score; Rectal neuroendocrine neoplasms; Prognostic model; Overall survival; Multicentre study

Core Tip: Compared with traditional methods, the GATIS score is a novel, highly accurate prognostic tool for rectal neuroendocrine neoplasms, offering superior predictive power for overall and progression-free survival.